BCL2 and non-Hodgkin lymphoma: The evidence indicates a reduced development of neutralizing antibodies against SARS-CoV-2 in patients with non-Hodgkin’s lymphoma undergoing active treatment, predominantly with anti-CD20 monoclonal antibodies, Bruton’s tyrosine kinase inhibitors and the Bcl2-inhibitor Venetoclax [6,12].